Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
Balance Sheet
14 Sheets · From 2022 to 2009Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 21.00 | 10.00 | 30.00 | 39.00 | 64.00 | 33.00 | 128.00 | 63.00 | 157.00 | 228.00 | 432.00 | 1,476.00 | 1,588.00 | 1,202.00 | |
|
Current
|
19.00 | 9.00 | 30.00 | 39.00 | 64.00 | 32.00 | 125.00 | 59.00 | 155.00 | 226.00 | 424.00 | 1,403.00 | 1,507.00 | 1,108.00 | |
| Cash And Equivalents | 13.00 | 7.00 | 9.00 | 18.00 | 14.00 | 29.00 | 122.00 | 56.00 | 150.00 | 222.00 | 415.00 | 1,390.00 | 413.00 | 235.00 | |
| Assets | 21.00 | 10.00 | 30.00 | 39.00 | 64.00 | 33.00 | 128.00 | 63.00 | 157.00 | 228.00 | 432.00 | 1,476.00 | 1,588.00 | 1,202.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -2.00 | -2.00 | 3.00 | |
| Short Term Investments | 3.00 | - - | 18.00 | 18.00 | 47.00 | 22.00 | 72.00 | 34.00 | 43.00 | 190.00 | 368.00 | 504.00 | 1,078.00 | 848.00 | |
| Other Current Assets | - - | - - | 1.00 | 1.00 | - - | 3.00 | 3.00 | 2.00 | 4.00 | 3.00 | 9.00 | 13.00 | 16.00 | 21.00 | |
|
Non Current
|
1.00 | 1.00 | - - | - - | - - | - - | 2.00 | 3.00 | 1.00 | 1.00 | 7.00 | 72.00 | 80.00 | 93.00 | |
| Property, Plant, Equipment (Net) | 1.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | 1.00 | 47.00 | 53.00 | 53.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 14.00 | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 15.00 | 8.00 | 3.00 | |
| Other Non Current Assets | - - | - - | - - | - - | - - | - - | 2.00 | 3.00 | - - | 1.00 | 6.00 | 9.00 | 19.00 | 21.00 | |
| Liabilities | 9.00 | 6.00 | 3.00 | 5.00 | 38.00 | 5.00 | 9.00 | 15.00 | 13.00 | 26.00 | 49.00 | 115.00 | 191.00 | 206.00 | |
|
Current
|
6.00 | 5.00 | 3.00 | 5.00 | 38.00 | 5.00 | 9.00 | 15.00 | 13.00 | 26.00 | 48.00 | 71.00 | 143.00 | 159.00 | |
| Accounts Payable | - - | - - | - - | - - | - - | - - | 4.00 | 5.00 | -1.00 | 12.00 | 23.00 | 23.00 | 71.00 | -4.00 | |
| Short Term Debt | - - | - - | - - | - - | - - | - - | - - | - - | - - | -17.00 | -48.00 | - - | 1.00 | 7.00 | |
| Deferred Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | - - | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 5.00 | 4.00 | 3.00 | 3.00 | 37.00 | - - | - - | - - | - - | 17.00 | 48.00 | 53.00 | 108.00 | 112.00 | |
|
Non Current
|
2.00 | 1.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | 43.00 | 48.00 | 46.00 | |
| Long Term Debt | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 41.00 | 45.00 | 43.00 | |
| Leasing Obligations | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 41.00 | 45.00 | 43.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 1.00 | 2.00 | 3.00 | |
| Equity | 11.00 | 4.00 | 27.00 | 34.00 | 25.00 | 28.00 | 118.00 | 48.00 | 143.00 | 201.00 | 382.00 | 1,360.00 | 1,397.00 | 996.00 | |
| Stockholders' Equity | 11.00 | 4.00 | 27.00 | 34.00 | 25.00 | 28.00 | 118.00 | 48.00 | 143.00 | 201.00 | 382.00 | 1,360.00 | 1,397.00 | 996.00 | |
| Retained Earnings | -110.00 | -130.00 | -137.00 | -161.00 | -198.00 | -242.00 | -306.00 | -389.00 | -460.00 | -559.00 | -772.00 | -1,130.00 | -1,712.00 | -2,452.00 | |
| Common Stock | - - | - - | - - | 166.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Profit | -22.00 | -14.00 | -9.00 | -20.00 | -52.00 | -43.00 | -64.00 | -83.00 | -70.00 | -98.00 | -212.00 | -357.00 | -581.00 | -740.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 122.00 | 134.00 | 167.00 | 32.00 | 214.00 | 260.00 | 415.00 | 428.00 | 594.00 | 751.00 | 1,144.00 | 2,481.00 | 3,099.00 | 3,453.00 | |
| Loss Other Compr. Income | - - | - - | -2.00 | -3.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | -3.00 |